Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 12/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16125422 | 0.92 | AGTR1 (0.44) | PPARGACHEEGFRERBB2 | |
| SCHEMBL16125416 | 0.89 | PPARG (0.51) | PPARG | |
| SCHEMBL16125409 | 0.85 | PPARG (0.60) | PPARGPPARA | |
| SCHEMBL28552677 | 0.83 | HCAR3 (0.62) | PPARGACHE | |
| SCHEMBL14120788 | 0.83 | PPARG (0.58) | PPARGACHE | |
| SCHEMBL16125425 | 0.83 | PPARG (0.53) | PPARGACHE | |
| SCHEMBL16125430 | 0.82 | PPARG (0.60) | PPARG | |
| SCHEMBL14120692 | 0.82 | PPARG (0.59) | PPARGPPARA | |
| SCHEMBL14977644 | 0.82 | PPARG (0.50) | PPARGACHE | |
| SCHEMBL25411952 | 0.81 | RECQL (0.51) | PPARGPLA2G4AEGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140288090-A1 | N-ARYLYLMETHYLINDAZOLE MODULATORS OF PPARG | SCRIPPS RESEARCH INSTITUTE, THE | 2014-09-25 | — | — | US | disclosed |
| US-20140288090-A1 | N-ARYLYLMETHYLINDAZOLE MODULATORS OF PPARG | SCRIPPS RESEARCH INSTITUTE, THE | 2014-09-25 | — | — | US | disclosed |
| WO-2013078237-A1 | N-ARYLYLMETHYLINDAZOLE MODULATORS OF PPARG | RIPKA AMY S (US) | 2013-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288090-A1 | N-ARYLYLMETHYLINDAZOLE MODULATORS OF PPARG | CDK5, CDK5R1, PPARG | PPARG 3/4885ACHE 3189/4885PLA2G4A 1343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.